SCHEMBL10074529

SCHEMBL10074529

CN1C(=O)NC(C)(c2cccc(Br)c2)NC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
HSD11B1 P28845 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MGLL Q99685 1/20 0.39
CHRNA1 P02708 1/20 0.38
CHRNG P07510 1/20 0.38
CHRNB1 P11230 1/20 0.38
CHRNB2 P17787 1/20 0.38
SLC6A2 P23975 1/20 0.38
CHRNB4 P30926 1/20 0.38
SLC6A4 P31645 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA4 P43681 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRND Q07001 1/20 0.38
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8245791 0.91 HCAR3 (0.37) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL8244493 0.83 HCAR3 (0.42) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL8247327 0.81 BACE1 (0.44) HCAR2HSD11B1MGLLCHRNA1CHRNG
SCHEMBL10074530 0.78 HCAR3 (0.37) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL7539840 0.75 KMT2A (0.46) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL20290106 0.75 TSHR (0.47) TSHRCYP2C19
SCHEMBL10074528 0.73 HCAR3 (0.36) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL7526798 0.72 ALDH1A1 (0.37) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL7550171 0.72 ALDH1A1 (0.37) HCAR3HCAR2HSD11B1ALDH1A1KMT2A
SCHEMBL10074531 0.72 BACE1 (0.36) HCAR3HCAR2HSD11B1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110682-B2 Preparation and use of compounds as aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-02-07 US disclosed
US-8110682-B2 Preparation and use of compounds as aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-02-07 US disclosed
US-20070010667-A1 Preparation and use of compounds as aspartyl protease inhibitors SCHERING CORPORATION 2007-01-11 US disclosed
US-20070010667-A1 Preparation and use of compounds as aspartyl protease inhibitors SCHERING CORPORATION 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010667-A1 Preparation and use of compounds as aspartyl protease inhibitors PRSS1, CTSS, CTSL HCAR3 3420/4885HCAR2 4340/4885HSD11B1 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.